Interferon β-1a and depression in relapsing-remitting multiple sclerosis: An analysis of depression data from the PRISMS clinical trial

Multiple Sclerosis

Volumn 7, Issue 4, 2001, Pages 243-248

  Patten, S B ^a   Metz, L M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Depression; Depressive disorders chemically induced; Depressive symptoms; Multiple sclerosis; Substance induced mood disorder

Indexed keywords

BETA1A INTERFERON; PLACEBO; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; EMPLOYMENT; EVALUATION AND FOLLOW UP; FEMALE; GENDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PSYCHOLOGIC TEST; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOM; ANXIETY; MENTAL HEALTH; ONSET AGE; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; TIME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE OF ONSET; ANXIETY; DEPRESSIVE DISORDER; EMPLOYMENT; FEMALE; HUMANS; INTERFERON-BETA; MALE; MENTAL HEALTH; MULTIPLE SCLEROSIS; PLACEBOS; PSYCHOLOGICAL TESTS; RECURRENCE; TIME FACTORS;

EID: 0034742275     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245801680209358     Document Type: Article

References (18)

1. Enterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
2. Interferon beta treatment of multiple sclerosis
3. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
4. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
5. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
6. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis
7. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment
8. Side effect profile of interferon beta-1b in MS: Results of an open label trial
9. The CES-D scale: A self-report depression scale for research in the general population
10. Validity of the Center for Epidemiological Studies Depression Scale in arthritis research
11. Assessing depressive symptoms in five psychiatric populations: A validation study
12. A scaled version of the General Health Questionnaire
13. Hopelessness and eventual suicide: A 10-year prospective study of patients hospitalized with suicidal ideation
14. Relationship between hopelessness and ultimate suicide: A replication with psychiatric outpatients